Amneal Pharmaceuticals, Inc. (AMRX), Friday announced financial outlook for the fiscal year 2025.
The company sees revenue in the range of $3.0 billion to $3.1 billion for the full year 2025.
Analysts, on average, estimate revenue of $2.92 billion for the same period.
The company projects adjusted earnings of $0.65 to $0.70 per share for the year.
Analysts, on average, expect earnings of $0.71 per share for the same year.
In the pre-market hours, Amneal's stock is trading at $8.60, up 2.63 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.